ERBB2 and neoplasm: In particular, stratification of BC patients for receptors status revealed that NEK2 is expressed at higher levels in ER- and PR-negative tumours (Fig. 1B,C), while no significant changes were observed when patients were stratified for HER2 amplification (Fig. 1D).